Clearmind Medicine (DB:CWY0) - Aandelenkoers, Nieuws & Analyse

CWY0 Overzicht aandelen

Clearmind Medicine Inc., een klinisch farmaceutisch bedrijf, ontwikkelt nieuwe psychedelische geneesmiddelen voor de behandeling van gezondheidsproblemen in Canada en daarbuiten. Meer informatie

CWY0 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( €5M )

De winst is de afgelopen 5 jaar met 52.4% per jaar gedaald

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

+ 1 meer risico

Clearmind Medicine Inc. Concurrenten

Biofrontera

XTRA:B8FK

€16.4m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€55.6m

Redx Pharma

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Clearmind Medicine
Historische aandelenkoersen
Huidige aandelenkoers	US$1.26
52 Week Hoogtepunt	US$6.00
52 Week Laag	US$0.88
Bèta	-1.52
11 maand verandering	-7.77%
3 maanden verandering	8.73%
1 Jaar Verandering	n/a
33 jaar verandering	-99.72%
5 jaar verandering	n/a
Verandering sinds IPO	-99.78%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	CWY0	DE Pharmaceuticals	DE Markt
7D	0%	-1.0%	0.2%
1Y	n/a	-19.3%	8.5%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe CWY0 presteerde ten opzichte van de German Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe CWY0 presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is CWY0's price volatile compared to industry and market?
CWY0 volatility
CWY0 Average Weekly Movement	9.5%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stabiele aandelenkoers: De aandelenkoers van CWY0 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van CWY0 is het afgelopen jaar gedaald van 23% naar 10%, maar is nog steeds hoger dan 75% van de German -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2017	n/a	Adi Zuloff-Shani	www.clearmindmedicine.com

Clearmind Medicine Inc., een klinisch farmaceutisch bedrijf, ontwikkelt nieuwe psychedelische geneesmiddelen voor de behandeling van gezondheidsproblemen in Canada en daarbuiten. Het ontwikkelt behandelingen voor stoornissen in het gebruik van alcohol, psychische stoornissen, comazuipen, obesitas en stofwisselingsstoornissen, en eetstoornissen. Het bedrijf ontwikkelt ook de MEAI-verbinding die zich in een IND-onderzoek bevindt voor de behandeling van alcoholstoornissen en in preklinisch onderzoek voor de behandeling van obesitas, gewichtsverlies, stofwisselingsstoornissen en verslaving.

Clearmind Medicine Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Clearmind Medicine zich tot de beurswaarde?
CWY0 fundamentele statistieken
Marktkapitalisatie	€5.18m
Inkomsten(TTM)	-€8.10m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.6x

Koers/Winstverhouding

Is CWY0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CWY0 resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$8.44m
Inkomsten	-US$8.44m

Laatst gerapporteerde inkomsten

Jul 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.08
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde CWY0 op de lange termijn?

Bekijk historische prestaties en vergelijking

CWY0 Overzicht aandelen

Risicoanalyse

Clearmind Medicine Inc. Concurrenten

XTRA:B8FK

€16.4m

DUSE:SBX

€27.9m

XTRA:HIGH

€55.6m

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025

Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment

Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Recent updates

Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025

Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment

Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression

Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities Exchange

Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration

Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million.

Clearmind Medicine Inc. has completed a Follow-on Equity Offering.

Clearmind Medicine Inc. has filed a Follow-on Equity Offering.

Clearmind Medicine Inc. has filed a Follow-on Equity Offering.

Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing Standards

Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Scisparc Ltd. Obesity Drug Showed Positive Results in A Pre-Clinical Trial

High number of new and inexperienced directors

Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based Treatment

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice

Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Clearmind Medicine Inc. announced that it expects to receive $2.25 million in funding

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use Disorder

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use Disorder

Clearmind Medicine Inc. Announces Board Appointments

Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark Office

Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based Compound

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100

Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical Trial

High number of new and inexperienced directors

Clearmind Medicine Inc. Common Shares Deleted from OTC Equity

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022

High number of new and inexperienced directors

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Clearmind Medicine Inc. Samenvatting

0.0x

-0.6x

Inkomsten en omzet